Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2299-5684
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention ; day:3 ; month:12 ; year:2020 ; pages:1-11
Pharmacological reports ; (3.12.2020), 1-11
- Urheber
-
Adamiak-Giera, Urszula
Czerkawska, Anna
Olędzki, Szymon
Kurzawski, Mateusz
Safranow, Krzysztof
Jastrzębska, Maria
Gawrońska-Szklarz, Barbara
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s43440-020-00197-w
- URN
-
urn:nbn:de:101:1-2021011218402484833675
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Adamiak-Giera, Urszula
- Czerkawska, Anna
- Olędzki, Szymon
- Kurzawski, Mateusz
- Safranow, Krzysztof
- Jastrzębska, Maria
- Gawrońska-Szklarz, Barbara
- SpringerLink (Online service)
Ähnliche Objekte (12)
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
Novel Aspects of Antiplatelet Drug Therapy in Patients Undergoing Percutaneous Coronary Intervention : Antiplatelet Therapy in Patients Undergoing PCI
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
Comparision Between Clopidogrel and Prasugrel On hs-CRP Levels Post Percutaneous Intervention
Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease
Priapism: A very rare complication of dual antiplatelet therapy after percutaneous coronary intervention
Antiplatelet agents
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
II. Inactive Mitglieder.
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
Novel Aspects of Antiplatelet Drug Therapy in Patients Undergoing Percutaneous Coronary Intervention : Antiplatelet Therapy in Patients Undergoing PCI
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
Comparision Between Clopidogrel and Prasugrel On hs-CRP Levels Post Percutaneous Intervention
Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease
Priapism: A very rare complication of dual antiplatelet therapy after percutaneous coronary intervention
Antiplatelet agents
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
II. Inactive Mitglieder.
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
Novel Aspects of Antiplatelet Drug Therapy in Patients Undergoing Percutaneous Coronary Intervention : Antiplatelet Therapy in Patients Undergoing PCI
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
Comparision Between Clopidogrel and Prasugrel On hs-CRP Levels Post Percutaneous Intervention
Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease
Priapism: A very rare complication of dual antiplatelet therapy after percutaneous coronary intervention
Antiplatelet agents
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention